Of Course 23andMe’s Business Plan Has Been to Sell Your Data All Along

Human genome-hawking company 23andMe has announced what reportedly is only the first of ten deals with big biotech companies: US-based health firm Genentech will pay up to $60 million for access to 23andMe's data to study Parkinson's. Read More >>